Exendin-4 treatment improves LPS-induced depressive-like behavior without affecting pro-inflammatory cytokines

Journal of Parkinson's Disease

Volumn 7, Issue 2, 2017, Pages 263-273

  Ventorp, Filip ^a   Bay Richter, Cecilie ^b   Nagendra, Analise Sauro ^e   Janelidze, Shorena ^a   Matsson, Viktor Sjödahl ^a   Lipton, Jack ^c   Nordström, Ulrika ^d   Westrin, Asa ^a   Brundin, Patrik ^e   Brundin, Lena ^e  

^a LUND UNIVERSITY   (Sweden)

^b AARHUS UNIVERSITY   (Denmark)

^c MICHIGAN STATE UNIVERSITY   (United States)

^d UMEÅ UNIVERSITY   (Sweden)

^e VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

Brain; Cytokine; Depression; Dopamine; Exendin 4; Inflammation; Parkinson's disease

Indexed keywords

EXENDIN 4; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MESSENGER RNA; MONOAMINE; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR; ANTIINFLAMMATORY AGENT; ANTIPARKINSON AGENT; AUTACOID; CYTOKINE; IL1B PROTEIN, RAT; PEPTIDE; VENOM;

ADULT; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN CORTEX; CELL VIABILITY; CEREBROSPINAL FLUID; CONTROLLED STUDY; CORPUS STRIATUM; CYTOKINE PRODUCTION; DEPRESSION; FLUORESCENCE ACTIVATED CELL SORTING; FORCED SWIM TEST; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPUS; MALE; MICROGLIA; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RAT; ANIMAL; BRAIN; CHEMICALLY INDUCED; DRUG EFFECTS; ENCEPHALITIS; ILLNESS BEHAVIOR; METABOLISM; MOTOR ACTIVITY; WISTAR RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIPARKINSON AGENTS; BRAIN; CYTOKINES; DEPRESSION; ENCEPHALITIS; ILLNESS BEHAVIOR; INFLAMMATION MEDIATORS; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; MALE; MICROGLIA; MOTOR ACTIVITY; PEPTIDES; RATS, WISTAR; TUMOR NECROSIS FACTOR-ALPHA; VENOMS;

EID: 85019346078     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-171068     Document Type: Article

References (53)

1. Goke R, Larsen PJ, Mikkelsen JD, & Sheikh SP (1995) Distribution of GLP-1 binding sites in the rat brain: Evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci, 7, 2294-2300.
2. Alvarez E, Martinez MD, Roncero I, Chowen JA, Garcia-Cuartero B, Gispert JD, Sanz C, Vazquez P, Maldonado A, de Caceres J, Desco M, Pozo MA, & Blazquez E (2005) The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. J Neurochem, 92, 798-806.
3. Kastin AJ, & Akerstrom V (2003) Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord, 27, 313-318.
4. Bertilsson G, Patrone C, Zachrisson O, Andersson A, Dannaeus K, Heidrich J, Kortesmaa J, Mercer A, Nielsen E, Ronnholm H, & Wikstrom L (2008) Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J Neurosci Res, 86, 326-338.
5. Isacson R, Nielsen E, Dannaeus K, Bertilsson G, Patrone C, Zachrisson O, & Wikstrom L (2011) The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test. Eur J Pharmacol, 650, 249-255.
6. Kobayashi K, Iwai T, Sasaki-Hamada S, Kamanaka G, & Oka J (2013) Exendin (5-39), an antagonist of GLP-1 receptor, modulates synaptic transmission via glutamate uptake in the dentate gyrus. Brain Res, 1505, 1-10.
7. Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D, Holloway HW, Powers K, Shen H, Egan JM, Sambamurti K, Brossi A, Lahiri DK, Mattson MP, Hoffer BJ, Wang Y, & Greig NH (2009) GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci U S A, 106, 1285-1290.
8. Harkavyi A, Abuirmeileh A, Lever R, Kingsbury AE, Biggs CS, & Whitton PS (2008) Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J Neuroinflammation, 5, 19.
9. Gault VA, & Holscher C (2008) GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. Eur J Pharmacol, 587, 112-117.
10. Abbas T, Faivre E, & Holscher C (2009) Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease. Behav Brain Res, 205, 265-271.
11. Wang XH, Li L, Holscher C, Pan YF, Chen XR, & Qi JS (2010) Val8-glucagon-like peptide-1 protects against Abeta1-40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats. Neuroscience, 170, 1239-1248.
12. Holscher C (2012) Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection. CNS Drugs, 26, 871-882.
13. Kim S, Moon M, & Park S (2009) Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease. J Endocrinol, 202, 431-439.
14. Athauda D, & Foltynie T (2016) The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: Mechanisms of action. Drug Discov Today, 21, 802-818.
15. Cao L, Li D, Feng P, Li L, Xue GF, Li G, & Holscher C (2016) A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson's disease by reducing chronic inflammation in the brain. Neuroreport, 27, 384-391.
16. Huang HJ, Chen YH, Liang KC, Jheng YS, Jhao JJ, Su MT, Lee-Chen GJ, & Hsieh-Li HM (2012) Exendin-4 protected against cognitive dysfunction in hyperglycemic mice receiving an intrahippocampal lipopolysaccharide injection. PLoS One, 7, e39656.
17. Darsalia V, Mansouri S, Ortsater H, Olverling A, Nozadze N, Kappe C, Iverfeldt K, Tracy LM, Grankvist N, Sjoholm A, & Patrone C (2012) Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats. Clin Sci (Lond), 122, 473-483.
18. McIntyre RS, Powell AM, Kaidanovich-Beilin O, Soczynska JK, Alsuwaidan M, Woldeyohannes HO, Kim AS, & Gallaugher LA (2013) The neuroprotective effects of GLP-1: Possible treatments for cognitive deficits in individuals with mood disorders. Behav Brain Res, 237, 164-171.
19. Athauda D, & Foltynie T (2015) The ongoing pursuit of neuroprotective therapies in Parkinson disease. Nat Rev Neurol, 11, 25-40.
20. Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Ell P, Soderlund T, Whitton P, Wyse R, Isaacs T, Lees A, Limousin P, & Foltynie T (2013) Exenatide and the treatment of patients with Parkinson's disease. J Clin Invest, 123, 2730-2736.
21. Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Kahan J, Fmedsci PE, Whitton P, Wyse R, Isaacs T, Lees A, Limousin P, & Foltynie T (2014) Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease. J Parkinsons Dis, 4, 337-344.
22. McGeer PL, & McGeer EG (2008) Glial reactions in Parkinson's disease. Mov Disord, 23, 474-483.
23. Smith RS (1991) The macrophage theory of depression. Med Hypotheses, 35, 298-306.
24. Miller AH, Maletic V, & Raison CL (2009) Inflammation and its discontents: The role of cytokines in the pathophysiology of major depression. Biol Psychiatry, 65, 732-741.
25. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, & Lanctot KL (2010) A meta-analysis of cytokines in major depression. Biol Psychiatry, 67, 446-457.
26. Steiner J, Bielau H, Brisch R, Danos P, Ullrich O, Mawrin C, Bernstein HG, & Bogerts B (2008) Immunological aspects in the neurobiology of suicide: Elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res, 42, 151-157.
27. Wang Q, Liu Y, & Zhou J (2015) Neuroinflammation in Parkinson's disease and its potential as therapeutic target. Transl Neurodegener, 4, 19.
28. Lindqvist D, Hall S, Surova Y, Nielsen HM, Janelidze S, Brundin L, & Hansson O (2013) Cerebrospinal fluid inflammatory markers in Parkinson's disease-associations with depression, fatigue, and cognitive impairment. Brain Behav Immun, 33, 183-189.
29. Cai Z, Fan LW, Kaizaki A, Tien LT, Ma T, PangY, Lin S, Lin RC, & Simpson KL (2013) Neonatal systemic exposure to lipopolysaccharide enhances susceptibility of nigrostriatal dopaminergic neurons to rotenone neurotoxicity in later life. Dev Neurosci, 35, 155-171.
30. Qin L, Wu X, Block ML, LiuY, Breese GR, Hong JS, Knapp DJ, & Crews FT (2007) Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia, 55, 453-462.
31. Bay-Richter C, Janelidze S, Hallberg L, & Brundin L (2011) Changes in behaviour and cytokine expression upon a peripheral immune challenge. Behav Brain Res, 222, 193-199.
32. Swiergiel AH, & Dunn AJ (2007) Effects of interleukin-1beta and lipopolysaccharide on behavior of mice in the elevated plus-maze and open field tests. Pharmacol Biochem Behav, 86, 651-659.
33. Cryan JF, Markou A, & Lucki I (2002) Assessing antidepressant activity in rodents: Recent developments and future needs. Trends Pharmacol Sci, 23, 238-245.
34. McNamara RK, Sullivan J, RichtandNM, Jandacek R, Rider T, Tso P, Campbell N, & Lipton J (2008) Omega-3 fatty acid deficiency augments amphetamine-induced behavioral sensitization in adult DBA/2J mice: Relationship with ventral striatum dopamine concentrations. Synapse, 62, 725-735.
35. Tonelli LH, Holmes A, & Postolache TT (2008) Intranasal immune challenge induces sex-dependent depressive-like behavior and cytokine expression in the brain. Neuropsychopharmacology, 33, 1038-1048.
36. Bonefeld BE, Elfving B, & Wegener G (2008) Reference genes for normalization:Astudy of rat brain tissue. Synapse, 62, 302-309.
37. Ford AL, Goodsall AL, Hickey WF, & Sedgwick JD (1995) Normal adult ramified microglia separated from other central nervous system macrophages by flow cytometric sorting. Phenotypic differences defined and direct ex vivo antigen presentation to myelin basic protein-reactive CD4+T cells compared. J Immunol, 154, 4309-4321.
38. Dantzer R, O'Connor JC, Freund GG, Johnson RW, & Kelley KW (2008) From inflammation to sickness and depression: When the immune system subjugates the brain. Nat Rev Neurosci, 9, 46-56.
39. Cechin SR, Perez-Alvarez I, Fenjves E, Molano RD, Pileggi A, Berggren PO, Ricordi C, & Pastori RL (2012) Antiinflammatory properties of exenatide in human pancreatic islets. Cell Transplant, 21, 633-648.
40. Rampersaud N, Harkavyi A, Giordano G, Lever R, Whitton J, & Whitton P (2012) Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson's disease with noradrenergic deficit. Br J Pharmacol, 167, 1467-1479.
41. Darsalia V, Hua S, Larsson M, Mallard C, Nathanson D, Nystrom T, Sjoholm A, Johansson ME, & Patrone C (2014) Exendin-4 reduces ischemic brain injury in normal and aged type 2 diabetic mice and promotes microglial M2 polarization. PLoS One, 9, e103114.
42. Yirmiya R (1996) Endotoxin produces a depressive-like episode in rats. Brain Res, 711, 163-174.
43. Chang SY, Kim DB, Ryu GR, Ko SH, Jeong IK, Ahn YB, Jo YH, & Kim MJ (2013) Exendin-4 inhibits iNOS expression at the protein level in LPS-stimulated Raw264. 7 macrophage by the activation of cAMP/PKA pathway. J Cell Biochem, 114, 844-853.
44. Abuirmeileh A, Harkavyi A, Rampersaud N, Lever R, Tadross JA, Bloom SR, & Whitton PS (2012) Exendin-4 treatment enhances L-DOPA evoked release of striatal dopamine and decreases dyskinetic movements in the 6-hydoxydopamine lesioned rat. J Pharm Pharmacol, 64, 637-643.
45. Drucker DJ, Philippe J, Mojsov S, Chick WL, & Habener JF (1987) Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A, 84, 3434-3438.
46. Kim KS, Park DH, Wessel TC, Song B, Wagner JA, & Joh TH (1993) A dual role for the cAMP-dependent protein kinase in tyrosine hydroxylase gene expression. Proc Natl Acad Sci U S A, 90, 3471-3475.
47. Lavicky J, & Dunn AJ (1995) Endotoxin administration stimulates cerebral catecholamine release in freely moving rats as assessed by microdialysis. J Neurosci Res, 40, 407-413.
48. Dunn AJ (1992) Endotoxin-induced activation of cerebral catecholamine and serotonin metabolism: Comparison with interleukin-1. J Pharmacol Exp Ther, 261, 964-969.
49. Robinson S, Sotak BN, During MJ, & Palmiter RD (2006) Local dopamine production in the dorsal striatum restores goal-directed behavior in dopamine-deficient mice. Behav Neurosci, 120, 196-200.
50. Tomer R, Goldstein RZ, Wang GJ, Wong C, & Volkow ND (2008) Incentive motivation is associated with striatal dopamine asymmetry. Biol Psychol, 77, 98-101.
51. Tadaiesky MT, Dombrowski PA, Figueiredo CP, Cargnin-Ferreira E, Da Cunha C, & Takahashi RN (2008) Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. Neuroscience, 156, 830-840.
52. Santiago RM, Barbieiro J, Lima MM, Dombrowski PA, Andreatini R, & Vital MA (2010) Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine. Prog Neuropsychopharmacol Biol Psychiatry, 34, 1104-1114.
53. Anderberg RH, Richard JE, Hansson C, Nissbrandt H, Bergquist F, & Skibicka KP (2016) GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality. Psychoneuroendocrinology, 65, 54-66.